207 research outputs found
Propagation-based phase-contrast tomography for high-resolution lung imaging with laboratory sources
Itinerant G-type antiferromagnet SrCr2As2 studied by magnetization, heat capacity, electrical resistivity, and NMR measurements
The physical properties of itinerant antiferromagnetic (AFM) SrCrAs
with body-centered tetragonal ThCrSi structure were investigated in
single crystalline and polycrystalline forms by electrical resistivity ,
heat capacity , magnetic susceptibility versus
temperature~ and magnetization versus applied magnetic field
isotherm measurements as well as As and Cr nuclear magnetic
resonance (NMR) measurements in the wide temperature range = 1.6--900 K.
From the and As NMR measurements, the G-type AFM state below
= 615(15) K has been determined, consistent with the previous
neutron-diffraction measurements. Direct evidence of magnetic ordering of the
Cr spins was shown by the observation of the Cr NMR spectrum under =
0. From the measurements on single-crystal SrCrAs under the
two different magnetic field directions and in the AFM state,
the Cr ordered moments are shown to align along the axis in the G-type AFM
state. The metallic state is directly evidenced by the , , and
NMR measurements, and the density of states at the Fermi energy in the AFM state is estimated to be 7.53 states/eV f.u. for both
spin directions which is almost twice the bare estimated
from first-principles calculations, suggesting an enhancement of the
conduction-carrier mass by a factor of two in the AFM state. The is found to be nearly constant below at least 100 K and is
independent of . The is found to show -linear behavior above
and exhibits positive curvature below where significant
loss of spin-disorder scattering upon magnetic ordering is observed.Comment: 14 pages, 12 figures, accepted for publication in Phys. Rev.
Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-in-Silico Approach Combining In Vitro Experiments and Machine Learning (vol 9, 393, 2018)
A Corrigendum on
Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-In silico Approach Combining In vitro Experiments and Machine Learning
by Zechendorf E, Vaßen P, Zhang J, Hallawa A, Martincuks A, Krenkel O, Müller-Newen G, Schuerholz T, Simon T-P, Marx G, Ascheid G, Schmeink A, Dartmann G, Thiemermann C and Martin L (2018). Front. Immunol. 9:393. doi: 10.3389/fimmu.2018.00393
In the original article, there was an error in the Author Contributions section. The wording used to declare the contribution of Elisabeth Zechendorf was not clear.
The new Author Contributions section appears below.
Conception and design: EZ, LM, GD, AS, and CT. In vitro experiments and data analyses: EZ, LM, TS, T-PS, AM, GM-N, OK, GM, and PV. Medical in silico experiments and data analyses: EZ, PV, JZ, GD, AS, LM, AH, and GA. EZ wrote the manuscript. Correction of the manuscript: EZ, PV, LM, CT, GM, GD, T-PS, and AS. All the authors reviewed and finally approved the manuscript.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated
Implants in the severely resorbed mandibles: whether or not to augment? What is the clinician’s preference?
Contains fulltext :
96000.pdf (publisher's version ) (Open Access)INTRODUCTION: The aim of this study is to inventory in the Netherlands which therapy is the clinician's first choice when restoring the edentulous mandible. MATERIAL AND METHODS: A questionnaire was sent to all Dutch Oral and Maxillofacial surgeons. As part of this, the surgeons were invited to treat five virtual edentulous patients, differing only in mandibular residual height. RESULTS: In cases of a sufficient residual height of 15 mm, all surgeons were in favour to insert solely two implants to anchor an overdenture. In case of a residual height of 12 mm, 10% of the surgeons choose for an augmentation procedure. If a patient was presented with a mandibular height of 10 mm, already 40% of the OMF surgeons executed an augmentation procedure. Most (80%) surgeons prefer the (anterior) iliac crest as donor site. The choice of 'whether or not to augment' was not influenced by the surgeon's age; however, the hospital, where he was trained, did. Surgeons trained in Groningen were more in favour of installing short implants in mandibles with reduced vertical height. DISCUSSION: As the option overdenture supported on two interforaminal implants is reimbursed by the Dutch health assurance, this treatment modality is very popular in the Netherlands. From a point of costs and to minimize bypass comorbidity, surgeons should be more reluctant in executing augmentation procedures to restore the resorbed edentulous mandible as it is dated in literature that also in mandibles with a residual height of 10 mm or less, solely placing implants, thus without an augmentation procedure in advance, is a reliable treatment option
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Background & Aims
Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC’s anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis.
Methods
Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC’s antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses.
Results
CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight.
Conclusions
CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC’s antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475)
- …